UnknownPhase 1NCT05410041

Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Boren Hospital
Principal Investigator
Kai Hu, MD/PhD
Beijing Boren Hospital
Intervention
CAR-NK-CD19 Cells(biological)
Enrollment
15 enrolled
Eligibility
18 years · All sexes
Timeline
20222024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05410041 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials